$241 Million is the total value of Artia Global Partners LP's 27 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 70.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SRPT | Sell | SAREPTA THERAPEUTICS INC | $6,929,178 | -21.6% | 57,162 | -25.9% | 2.88% | -5.4% |
| TMO | Sell | THERMO FISHER SCIENTIFIC INC | $1,067,513 | -59.8% | 2,109 | -58.5% | 0.44% | -51.5% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $615,202 | -66.8% | 41,261 | -75.6% | 0.26% | -59.9% |
| MOR | Exit | MORPHOSYS AGsponsored ads | $0 | – | -43,499 | -100.0% | -0.11% | – |
| BNTX | Exit | BIONTECH SEsponsored ads | $0 | – | -37,108 | -100.0% | -1.38% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -102,940 | -100.0% | -3.23% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -244,861 | -100.0% | -3.32% | – |
| IMGN | Exit | IMMUNOGEN INC | $0 | – | -543,358 | -100.0% | -3.53% | – |
| MRNA | Exit | MODERNA INC | $0 | – | -84,719 | -100.0% | -3.55% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -52,275 | -100.0% | -5.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 4 | Q3 2023 | 25.8% |
| MERCK & CO INC | 4 | Q3 2023 | 14.1% |
| ARGENX SE | 4 | Q3 2023 | 12.3% |
| LILLY ELI & CO | 4 | Q3 2023 | 14.5% |
| ABBVIE INC | 4 | Q3 2023 | 5.6% |
| ASTRAZENECA PLC | 4 | Q3 2023 | 5.4% |
| SEAGEN INC | 4 | Q3 2023 | 4.5% |
| BIOMARIN PHARMACEUTICAL INC | 4 | Q3 2023 | 4.3% |
| NEUROCRINE BIOSCIENCES INC | 4 | Q3 2023 | 2.1% |
| VERTEX PHARMACEUTICALS INC | 4 | Q3 2023 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.